Fasting plasma glucose control among nigerians with metabolic syndrome

Simple item page
dc.contributor.authorAdediran, O.S
dc.contributor.authorFasanmade, O.A
dc.contributor.authorOgbera, A.O
dc.contributor.authorOhwovoriole, A.E
dc.date.accessioned2020-01-21T13:34:53Z
dc.date.available2020-01-21T13:34:53Z
dc.date.issued2007
dc.descriptionStaff publicationsen_US
dc.description.abstractIntroduction: Metabolic Syndrome consists of many diseases that predispose to cardiovascular events including type 2 diabetes mellitus, systemic hypertension, central obesity, dyslipidaemia, endothelial dysfunction and inflammation. Hence, glycaemic management of these cluster of diseases might take a different pattern compared with only type 2 diabetes mellitus. Objective: To determine the levels of fasting plasma glucose (FPG) and the type of oral antidiabetic drugs patients with metabolic syndrome are receiving. To relate the FPG to the type of medications the patients were using. Materials and Methods: One-hundred and ninety-two patients with type 2 DM attending Diabetic clinic of the Lagos University Teaching Hospital (LUTH), Lagos were randomly enrolled for the study. Ninety-six of the patients had metabolic syndrome X (presence of hypertension and obesity in addition to type 2 DM), while the rest had only type 2 DM. History was obtained through a questionnaire and they were physically examined. Blood samples were obtained twice for plasma glucose estimation. Results: There were more metabolic syndrome subjects on combination of sulponylurea and metformin (80%) than the controls (28%), (<0.01). While many of the control subjects were on sulphonylurea alone (56% vs 7%, <0.01 ), none was on metformin alone. The mean fasting plasma glucose were comparable among the groups (5.63.8mmol/l vs 5.52.9mmol/l ), =0.36. Conclusion: Insulin resistance seems to plays a more prominent role in MS and patients benefited more from either combination therapy or metformin alone whereas  cells dysfunction may be more important among patients with T2DM alone and they benefited more from sulphonylurea.en_US
dc.identifier.citationAdediran, O.S., Fasanmade, O.A., Ogbera, A.O. and Ohwovoriole, AE. (2007). Fasting plasma glucose control among nigerians with metabolic syndrome. Highland Medical Research Journal, 5(1):49-53en_US
dc.identifier.issn1596-2407
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/7476
dc.language.isoenen_US
dc.publisherHighland Medical research limiteden_US
dc.relation.ispartofseriesHighland Medical Research Journa;Vol.5(1)
dc.subjectPlasma glucoseen_US
dc.subjectOral hypoglycaemic agentsen_US
dc.subjectNigeriansen_US
dc.subjectMetabolic syndromeen_US
dc.subjectDiabetesen_US
dc.subjectResearch Subject Categories::MEDICINEen_US
dc.titleFasting plasma glucose control among nigerians with metabolic syndromeen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Fasting plasma glucose control among nigerians with metabolic syndrome. | Adediran | Highland Medica.pdf
Size:
200.66 KB
Format:
Adobe Portable Document Format
Description:
Abstract
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine- Scholarly Publications